Arcus Biosciences, Inc.

Guillaume Mata

Manmohan Reddy Leleti

Kenneth Victor Lawson

Joel Worley Beatty

Samuel Lawrie Drew

Artur Karenovich Mailyan

Jay Patrick Powers

Xuelei Yan

Brandon Reid Rosen

Jenna Leigh Jeffrey

Balint Gal

Clayton Hardman

Zhang Wang

Kai Yu

Matthew Epplin

Jaroslaw Kalisiak

Hyunyoung Moon

Jeremy Thomas Andre Fournier

Karl T Haelsig

Debashis Mandal

Erick Allen Lindsey

Yongli Su

Anh Thu Tran

Steven Donald Jacob

Tezcan Guney

Jeremy Fournier

Dillon Harding Miles

Rhiannon Thomas-Tran

Ehesan Ui Sharif

Srinivas Paladugu

Karen Yir Jing Chen

Pradeep Nareddy

Monika Yadav

Manjunath Lamani

Srijita Bhowmik

Jiang Zhu

Masa Podunavac

Dongdong Liu

Compounds that inhibit PI3Kγ, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by PI3Kγ.

2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds

The present disclosure is directed to compounds having a structure according to Formula I, and compositions containing those compounds. Methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.

Thiazole compounds and methods of use thereof

The present disclosure describes processes and intermediates useful for preparing a compound of Formula (Xa) or Formula (Xb). The processes and intermediates can be used to prepare the compounds of the disclosure at multigram or kilogram scale.

Process for preparing tetralin compounds

Compounds that inhibit HIF-2α, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2α.

Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha

The present disclosure is directed to compounds that are inhibitors of HIF-2α having a structure according to Formula I, and compositions containing those compounds. Methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.

Inhibitors of HIF-2α and methods of use thereof

Compounds that inhibit HIF-2&#x3b1;, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2&#x3b1;.

Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2&#x3b1;

Growing community of inventors

Berkeley, CA, United States of America

Guillaume Mata